-
(单词翻译:双击或拖选)
FDA advisors1 recommend the Novavax COVID vaccine2
The Food and Drug Administration advisory4 committee recommends the agency authorize5 another COVID-19 vaccine in the hopes it might entice6 more people to get vaccinated7.
STEVE INSKEEP, HOST:
The United States is close to approving another COVID-19 vaccine. A Food and Drug Administration advisory committee recommended that the agency authorize it. NPR health correspondent Rob Stein told us this vaccine works differently than others.
ROB STEIN, BYLINE8: It's what's known as a protein subunit vaccine because it works by injecting a protein from the virus along with a substance called an adjuvant, which kind of turbocharges the immune reaction to that protein. And a study involving about 30,000 people found two shots of the vaccine three weeks apart was about 90% effective at protecting people against COVID-19.
INSKEEP: Isn't that about the same as the vaccines9 we already have?
STEIN: Yeah, you're right. This Novavax vaccine looks like it probably works just about as well as the Moderna and the Pfizer-BioNTech injections. But the Novavax vaccine works in an entirely10 different way. It uses that much more traditional approach, a strategy that's been used for decades to make many other vaccines. So the hope is that it just may make it more appealing to some of the millions of people who still haven't gotten vaccinated, you know, people who just don't like the idea of using the brand-new mRNA technology that the Moderna and Pfizer-BioNTech vaccines use. Those vaccines inject genetic11 coding that turns cells its little factories that churn out a protein from the virus, and that makes some people nervous and has been the fodder12 for lots of misinformation that has made some people avoid getting vaccinated. Now, the FDA says the Moderna and Pfizer-BioNTech vaccines are very safe, but here's how Dr. Peter Marks from the FDA put it during a daylong meeting of the agency's outside advisers13 yesterday.
(SOUNDBITE OF ARCHIVED RECORDING)
PETER MARKS: A protein-based alternative may be more comfortable for some in terms of their acceptance of vaccine.
STEIN: Now, some experts are skeptical14 that this distinction will make much of a difference. And there are still some questions about the Novavax vaccine. It may cause the same kind of rare inflammation of the heart that sometimes occurs in people who get the Moderna and Pfizer-BioNTech vaccines. Here's Dr. Arthur Reingold from the University of California, Berkeley, one of the FDA's advisers who endorsed15 the vaccine at the meeting.
(SOUNDBITE OF ARCHIVED RECORDING)
ARTHUR REINGOLD: I'm hoping to be proven wrong and that there are large numbers of people who sign up for this vaccine who wouldn't take an mRNA vaccine, but count me as skeptical about that.
STEIN: It's also unclear how well the Novavax vaccine works against the omicron variant16, since that strain wasn't circulating when the vaccine was tested. Several omicron subvariants are now dominant17 in the U.S., including two that are now on the rise that are even better at dodging18 the immune system.
INSKEEP: OK, I guess we don't have final-final approval then for this new Novavax vaccine. What happens next?
STEIN: That's right. That's right. The FDA will now have to decide whether to go along with the advisory committee's recommendation and authorize the vaccine. It doesn't have to, but it usually does. And if the FDA does greenlight the Novavax vaccine, the Centers for Disease Control and Prevention will weigh in with recommendations about how best to use it. We'll also have to see how much of this vaccine will actually become available. One of the reasons this vaccine wasn't authorized19 sooner was the company has had problems ramping20 up production. But another role this vaccine might be able to play is as a booster. The federal government's planning another big booster campaign in the fall to try to protect people against another potential surge next winter, and the Novavax vaccine might end up being one of the options for that.
INSKEEP: Rob, thanks very much for your reporting.
STEIN: Sure thing. It's always a pleasure, Steve.
INSKEEP: That's NPR's Rob Stein.
1 advisors | |
n.顾问,劝告者( advisor的名词复数 );(指导大学新生学科问题等的)指导教授 | |
参考例句: |
|
|
2 vaccine | |
n.牛痘苗,疫苗;adj.牛痘的,疫苗的 | |
参考例句: |
|
|
3 transcript | |
n.抄本,誊本,副本,肄业证书 | |
参考例句: |
|
|
4 advisory | |
adj.劝告的,忠告的,顾问的,提供咨询 | |
参考例句: |
|
|
5 authorize | |
v.授权,委任;批准,认可 | |
参考例句: |
|
|
6 entice | |
v.诱骗,引诱,怂恿 | |
参考例句: |
|
|
7 vaccinated | |
[医]已接种的,种痘的,接种过疫菌的 | |
参考例句: |
|
|
8 byline | |
n.署名;v.署名 | |
参考例句: |
|
|
9 vaccines | |
疫苗,痘苗( vaccine的名词复数 ) | |
参考例句: |
|
|
10 entirely | |
ad.全部地,完整地;完全地,彻底地 | |
参考例句: |
|
|
11 genetic | |
adj.遗传的,遗传学的 | |
参考例句: |
|
|
12 fodder | |
n.草料;炮灰 | |
参考例句: |
|
|
13 advisers | |
顾问,劝告者( adviser的名词复数 ); (指导大学新生学科问题等的)指导教授 | |
参考例句: |
|
|
14 skeptical | |
adj.怀疑的,多疑的 | |
参考例句: |
|
|
15 endorsed | |
vt.& vi.endorse的过去式或过去分词形式v.赞同( endorse的过去式和过去分词 );在(尤指支票的)背面签字;在(文件的)背面写评论;在广告上说本人使用并赞同某产品 | |
参考例句: |
|
|
16 variant | |
adj.不同的,变异的;n.变体,异体 | |
参考例句: |
|
|
17 dominant | |
adj.支配的,统治的;占优势的;显性的;n.主因,要素,主要的人(或物);显性基因 | |
参考例句: |
|
|
18 dodging | |
n.避开,闪过,音调改变v.闪躲( dodge的现在分词 );回避 | |
参考例句: |
|
|
19 authorized | |
a.委任的,许可的 | |
参考例句: |
|
|
20 ramping | |
土堤斜坡( ramp的现在分词 ); 斜道; 斜路; (装车或上下飞机的)活动梯 | |
参考例句: |
|
|